Vivus stock suffers on likely EU rejection; Watson recalls painkiller on potency worries;

 @FiercePharma: U.K.'s Rosemont Pharmaceuticals is up for sale. Value est. at £200M; specializes in liquid formulations--Sky News. Report | Follow @FiercePharma

> Vivus ($VVUS) stock is on the slide after the company announced it expects its new weight-loss drug to be rejected by European regulators in October. Report

> Watson Pharmaceuticals ($WPI) recalled two lots of its hydrocodone and acetaminophen painkiller because of the possibility that the pills may be more potent than intended. Report

> Valeant Pharmaceuticals ($VRX) paid $62.5 million to buy the U.S. rights to Visudyne, a treatment for age-related vision loss, from developer QLT. Report

> Ireland's Elan tapped Hans Peter Hasler as its incoming chief operating officer, as of Oct. 1; he is currently a non-executive director on the company's board. Report

> Canadian health advocates protested provisions of a free trade deal between Canada and the EU, saying they will hike drug costs and benefit Big Pharma. Report

Medical Device News

 @FierceMedDev: Tribogenics pulled in a $6.2M Series A round, to help develop portable X-ray sources for medical imaging. Release | Follow @FierceMedDev

 @MarkHFierce: Look at Teleflex, getting a 510(k) for a continuous peripheral nerve block catheter--a new anesthesia tool. Release | Follow @MarkHFierce

 @DamianFierce: Medtronic is making noise in India, appointing a new board member and committing $6M in grant money there. More | Follow @DamianFierce

> Boston Sci rolls out fresh cardiac products for two international launches. Story

> South Korea's SK Telecom dives into China's medtech industry. Item

Biotech News

 @FierceBiotech: In case you missed it last week, check out our 2012 Fierce 15 report: Report | BPA 2012 Slideshow | Follow @FierceBiotech

 @JohnCFierce: Peregrine is now a penny stock company, down 85%. And somewhere lawyers are beginning a new day, aflutter with litigious thoughts. | Follow @JohnCFierce

 @RyanMFierce: Virtual R&D groups make sense in cases where a pharma might otherwise just pull the plug on R&D in a field like CNS. More | Follow @RyanMFierce

> Mallinckrodt swallows CNS Therapeutics' drug pipeline in $100M buyout. News

> Novo Nordisk boosts China R&D with $100M diabetes research project. Report

> Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data. Article

CRO News

> EU experts call for clinical trials to focus on the elderly. Report

> Big Pharmas unite to improve clinical development. Article

> CMOs move toward disposable manufacturing tech. More

> Covance taps big data outfit for diabetes R&D. Story

Biotech IT News

> Google VC unit angles for further life sciences investments. Article

> NYC startup Medikly caters to pharma interactions with docs. More

> Accelrys goes late-stage in R&D software game. Story

> AstraZeneca builds virtual neuroscience drug unit byte by byte. Report

And Finally... A new study identified genetically distinct types of breast cancer and the genetic changes that are their hallmarks. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.